Results 191 to 200 of about 1,338,841 (294)

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

Leakage, Welfare, and Cost-Effectiveness of Carbon Policy

, 2013
Kathy Baylis, Don Fullerton, Daniel H. Karney   +2 more
openalex   +1 more source

A Scoping Review on Artificial Intelligence–Supported Interventions for Nonpharmacologic Management of Chronic Rheumatic Diseases

Arthritis Care &Research, EarlyView.
This review summarizes artificial intelligence (AI)‐supported nonpharmacological interventions for adults with chronic rheumatic diseases, detailing their components, purpose, and current evidence base. We searched Embase, PubMed, Cochrane, and Scopus databases for studies describing AI‐supported interventions for adults with chronic rheumatic diseases.
Nirali Shah, Alexis Castellanos, Yen Chen, John Piette, Amy Bucher, Susan Murphy   +5 more
wiley   +1 more source

Cost-effectiveness of smoke-free interventions: A systematic review. [PDF]

Tob Prev Cessat
Werner K, Lin TK, Binshehah RH, Shahin MA, Al-Zalabani AH, Hamza MM, Alsukait RF, Cetinkaya V, Alghaith T.   +8 more
europepmc   +1 more source

Lived and Care Experiences of Chronic Musculoskeletal Shoulder Pain in Australian Adults: A Qualitative Study

Arthritis Care &Research, EarlyView.
Objective Australian evidence on lived and care experiences of chronic musculoskeletal shoulder pain (CMSP), irrespective of disorder classification or disease, is limited. However, such evidence is important for person‐centered care and informing local service pathways and care guidelines or standards.
Sonia Ranelli, Joanne E. Jordan, Ilana N. Ackerman, Alison Thorpe, Jennifer G. Persaud, Linda J. Woodhouse, Jason Chua, Ben Horgan, Andrew M. Briggs   +8 more
wiley   +1 more source

A bridge to clean cooking? The cost-effectiveness of energy-efficient biomass stoves in rural Senegal

Gunther Bensch, Marc Jeuland, Luciane Lenz, Ousmane Ndiaye   +3 more
openalex   +1 more source

Breakeven, Cost Benefit, Cost Effectiveness, and Willingness to Pay for Web-Based Versus Face-to-Face Education Delivery for Health Professionals [PDF]

, 2012
Stephen Maloney, Romi Haas, Jenny Keating, Elizabeth Molloy, Brian Jolly, Jane Sims, Prue Morgan, Terry Haines   +7 more
openalex   +1 more source

Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis

, 2021
Matthijs Versteegh, Simone Huygens, Beatrijs W.H. Wokke, Joost Smolders   +3 more
openalex   +1 more source

Cost-Effectiveness of Risk-Based Screening for Asymptomatic Carotid Artery Stenosis. [PDF]

MDM Policy Pract
Zhu J, Jhang J, Yu H, Mushlin AI, Kamel H, Alemayehu N, Giardina JC, Gupta A, Pandya A.   +8 more
europepmc   +1 more source

LOXHD1 and RHOB Expression by Monocytes Predicts Progressive Systemic Sclerosis associated Interstitial Lung Disease

Arthritis Care &Research, Accepted Article.
Objective A leading cause of death among scleroderma (SSc) patients, interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M Padilla, Robert Lafyatis, Kevin F Gibson, Christina Morse, Eleanor Valenzi, Xiaoping Chen, Xiaoyun Li, Yanwu Zhao, Yongseok Park, Dana Ascherman, Jonathan Minden, Robyn Domsic, Yingze Zhang, Daniel J Kass   +13 more
wiley   +1 more source